Table 1.
Sample Type | Subgroup | No. of Samples | Median dT, Days (IQR) | No. (%) of Females | Median Age, Years (IQR) | History of Immunosuppressive Condition or Medication, No. (%) |
---|---|---|---|---|---|---|
Convalescent | WT (adults) | 30 | 104 (94–119) | 14 (47) | 62 (51–69) | 0 (0) |
WT (children) | 20 | 124 (116–129) | 7 (35) | 11 (7–14) | 0 (0) | |
Alpha | 30 | 88 (47–104) | 12 (40) | 56 (42–65) | 14 (47) | |
Delta | 6 | 18 (10–23) | 5 (83) | 65 (56–73) | 4 (67) | |
Infected and vaccinated | … | 25 | 54 (23–91) | 16 (64) | 55 (48–59) | 1 (4) |
Vaccinated | A/A (1–2 mo) | 30 | 49 (48–52) | 20 (67) | 64 (60–66) | 2 (7) |
A/A (4–6 mo) | 30 | 154 (146–158) | 23 (77) | 55 (48–60) | 0 (0) | |
M/M (1–2 mo) | 30 | 51 (48–54) | 20 (67) | 59 (49–61) | 1 (3) | |
M/M (4–6 mo) | 16 | 139 (131–145) | 9 (56) | 70 (51–83) | 1 (6) | |
P/P (1–2 mo) | 30 | 51 (49–54) | 20 (67) | 58 (52–66) | 1 (3) | |
P/P (4–6 mo) | 30 | 152 (141–160) | 25 (83) | 38 (30–53) | 0 (0) | |
A/M | 20 | 153 (150–154) | 16 (80) | 41 (29–56) | 0 (0) | |
A/P | 20 | 151 (144–157) | 19 (95) | 48 (42–56) | 0 (0) | |
P/P/P | 20 | 14 (14–26.5) | 13 (65) | 33 (29–44) | 2 (12) | |
Negative | … | 15 | … | 8 (53) | 37 (29–41) | 0 (0) |
Abbreviations: A/A, 2-dose AZD1222; A/M, first dose AZD1222, second dose mRNA-1273; A/P, first dose AZD1222, second dose BNT162b2; dT, time post-infection/last vaccination dose; IQR, interquartile range; M/M, 2-dose mRNA-1273; P/P, 2-dose BNT162b2; P/P/P, 3-dose BNT162b2; WT, wild-type (B.1 isolate).